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Patients with acute lymphoblastic leukaemia (ALL) are at high
venous thromboembolism (VTE) risk (affecting between 1.5 and
37%1,2) with up to 50% affecting the cerebral veins.3–6
Thrombosis is a potentially avoidable source of morbidity and
mortality in ALL patients, particularly during the early phases of
chemotherapy.7,8 Prevention and treatment of thrombosis with
antithrombotic drugs may be complicated by co-existent bleeding
risk due to factors such as thrombocytopenia and the need for
procedures.
Conventional clotting tests (platelet count (PLT), prothrombin
time (PT), partial thromboplastin time (PTT), Clauss ﬁbrinogen) only
measure isolated components of haemostasis with no measure of
cellular/plasma interactions, platelet function, natural anticoagu-
lants, Von Willebrand factor (VWF) and ﬁbrinolysis. Therefore, when
complex, multiple reciprocal changes occur, these tests are poor at
predicting overall balance.2,3 Consistent with this, in patients with
ALL, conventional tests are often abnormal, implying a bleeding
tendency when in fact, thrombosis is the greater risk. Global
clotting tests are an alternative approach measuring the net effect
of multiple pathways. Thromboelastography (for example, ROTEM)
tests whole-blood clot formation and ﬁbrinolysis, activated by
intrinsic (INTEM) or extrinsic pathways (EXTEM). FIBTEM tests
ﬁbrinogen in isolation and thrombin generation reﬂects the net
balance of pro- and anticoagulant proteins in plasma. In other
similar complex coagulopathies (for example, liver failure, trauma
and cardiac surgery), global tests are clinically useful and may be
more reﬂective of haemostatic balance.9–12
To comprehensively evaluate the coagulopathy in ALL patients
before and during induction chemotherapy (the highest VTE risk
period for current UK treatment protocols), we undertook a
prospective, single centre longitudinal cohort study (GlobALL study
REC approval ref 14/EM/1315) in which blood samples at multiple
time points were analysed in parallel using global, conventional
clotting tests, speciﬁc factor and anticoagulant levels.
Newly diagnosed adults and children with ALL commencing
intensive chemotherapy at UHBristol NHS Foundation trust were
eligible for study enrolment. Participants gave informed written
consent. VTE and bleeding events were recorded for the ﬁrst 90 days
of treatment. ALL treatment was with UKALL2011 (patients o25 y,
Peg-Asparaginase d4 and d18), UKALL14 (patients 25–65, Peg-
Asparaginase D18 and d4 if o40 y) and UKALL60+ protocols
(patients 465 no Peg-Asparaginase).13 Adult patients (418 y)
routinely received low molecular weight heparin (LMWH) thrombo-
prophylaxis in hospital if no contraindications but not on discharge.
There was no routine thromboprophylaxis in children o18 y.
Samples from 20 healthy adult controls were also obtained.
Blood samples were collected into EDTA and trisodium citrate at
d0 (pre-treatment), d4, d5 (only if d4 Peg-Asparaginase was
administered), d10, d18, d19 (only if d18 Peg-Asparaginase was
administered), d24, d29 and d36. Each blood sample underwent
analysis using standard laboratory methods for PLT, PT, activated
PTT, Clauss ﬁbrinogen, D dimer level, activities of antithrombin,
protein C, coagulation factor VIII, antigenic levels of VWF:Ag and
protein S. Global coagulation analysis of whole blood was
performed within 4 h of venepuncture using a ROTEM analyser
and the EXTEM, INTEM and FIBTEM tests. Plasma samples were
analysed by calibrated automated thrombography to measure
thrombin generation using an Ascent ﬂuorometer (Thermo-Lab
systems, Helsinki, Finland) and Stago PPP LOW (1pM tissue factor)
reagent.
Statistical analysis was performed using GraphPad Prism
(La Jolla, CA, USA) and SAS (Buckinghamshire, UK). One-way
analysis of variance (ANOVA) comparison between groups using
Tukey’s multiple comparisons test was used. Longitudinal
distribution of the data over the study period was measured with
a repeated measures ANOVA using an autoregressive variance
matrix for normally distributed data and Kruskal–Wallis test for
non-parametric data. A P-value of less than 0.05 was considered
signiﬁcant.
Thirty-ﬁve patients were recruited between January 2015 and
January 2016 (24 male, 31B, 4T lineage, median age 12 y, range 18
months 67 y). Twenty-nine patients received d4 and d18 Peg-
Asparaginase, three received d18 only and three did not receive
Asparaginase (as BCR-ABL positive). Thirty-four patients had
central venous line for induction chemotherapy. Six patients
received LMWH thromboprophylaxis during induction for a
median duration of 15 days (range 4–42). Out of 232 blood
samples collected, 221 were of sufﬁcient quality to process.
The overall VTE incidence was 17% (6 out of 35) (median age
32 y, range 14–67 y), including 2 patients on preceding LMWH
thromboprophylaxis. Two life-threatening cerebral VTE occurred,
three line-associated clots and one deep vein thrombosis (latter
patient did not receive Peg-Asparaginase). Thrombosis was
diagnosed at a median 35 days after chemotherapy initiation
(range day 10–50). All events occurred when PLTs 450 × 109/l.
Two adults had clinically relevant non-major bleeding and overt
consumptive coagulopathy prior to treatment.
Compared to 20 healthy controls (Table 1) and appropriate
reference ranges for age and gender, before induction chemo-
therapy (d0), patients with ALL showed multiple abnormalities in
the panel of haemostasis tests (Table 1). The tests which showed
the highest proportion of values outside reference interval were
reduced PLT, PTT, thrombin generation (ETP (endogenous
thrombin potential) and peak) and EXTEM maximal clot ﬁrmness
(MCF) (425% of results below reference intervals), and increased
Clauss ﬁbrinogen, D dimer, VWF:Ag, FVIII, FIBTEM MCF (425% of
results above reference intervals; Table 1).
Over the ﬁrst 36 days of induction chemotherapy, (Table 1),
there were dynamic changes in haemostasis tests. By d29, the
tests which showed the highest proportion of values outside
reference interval were reduced Clauss Fibrinogen, thrombin
generation (ETP and peak), antithrombin, FIBTEM MCF and EXTEM
MCF (425% of results below reference intervals) and increased
PT, PTT, VWF:Ag, FVIII and EXTEM clotting time (CT) (425% of
results above reference intervals; Table 1). The most clinically and
statistically signiﬁcant changes (d29 compared to d0) were
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increased PLT, PT, PTT and a simultaneous reduction of Clauss
ﬁbrinogen, FIBTEM MCF, antithrombin and protein S (Po0.05).
Correlation has previously been reported between Clauss
ﬁbrinogen and FIBTEM MCF, and between PLT and EXTEM
MCF.14,15 In this ALL cohort, Clauss ﬁbrinogen correlated with
FIBTEM MCF (r2 = 0.5417, n= 221; Po0.0001). However, in
comparison to healthy controls (n= 20) and a cohort of cardiac
surgery patients (n= 2146) the y intercept of the correlation curves
was higher in ALL patients (Po0.0001) indicating that for any
given Clauss ﬁbrinogen results, the corresponding FIBTEM MCF
was higher (Figure 1). PLT and EXTEM MCF also correlated
(r2 = 0.4080; n= 221; Po0.0001). There was no correlation
between any other ROTEM and conventional clotting test result
in ALL patients or controls including PT vs EXTEM CT (measuring
time to clot, extrinsic pathway), PTT vs INTEM CT (measuring time
to clot, intrinsic pathway) conﬁrming that these assays are not
interchangeable.
Before induction chemotherapy (d=0), patients with ALL who
later developed VTE (n=6) had higher PLT, VWF:Ag, Clauss
ﬁbrinogen and FIBTEM MCF than those who did not (Po0.05,
Table 1). During induction chemotherapy (over 36 days), patients
who developed VTE had higher thrombin generation (ETP and
peak), PLT, VWF:Ag, EXTEM MCF and shorter INTEM CT and EXTEM
CT compared to patients without VTE (Po0.05, Table 1). There were
no other differences between the VTE and no VTE groups either at
d0 or during induction chemotherapy, including lowest values of
antithrombin (trough), PT or PTT. None of the study patients had
positive IgM or IgG anticardiolipin antibodies or prothrombin gene
mutation, and only one had factor V Leiden (homozygous).
Interestingly, this latter patient did not develop VTE.
The GlobALL study conﬁrms VTE is an important ALL complica-
tion and may occur in spite of LMWH thromboprophylaxis. Before
and during the ﬁrst 36 days of treatment, patients with ALL have
deranged complex, dynamic abnormalities in haemostasis. The
results of this study are consistent with the existing literature
describing haemostatic abnormalities in patients with ALL.1
However, to our knowledge this is the most comprehensive
evaluation at multiple time points and includes assessment of
novel approaches such as ROTEM.
Many of the signiﬁcant prothrombotic changes, such as high
VWF, VIII and low antithrombin, are not tested by conventional
tests explaining why these are poorly representative and may
overestimate bleeding and underestimate VTE risk. The raised VIII,
VWF and ﬁbrinogen before treatment suggest a potential role for
endothelial activation in VTE pathogenesis, which could represent
a new target for prevention strategies.
This is the ﬁrst study to have systematically evaluated ROTEM in
ALL. Although PT and PTT (conventional tests) measure similar
haemostasis pathways to EXTEM CT and INTEM CT (global
haemostasis tests), respectively, results did not correlate. In
addition, patients with abnormal PT and PTT results frequently
had EXTEM CT and INTEM CT within the normal range. For
example, 49% of patients had an abnormally short PTT pre-
treatment and at d29, 42% had an abnormally long APTT. In
comparison, only 9% of patients had an abnormally long INTEM CT
pre-treatment, and at d29 only 12% of patients had an abnormally
long INTEM CT. This combined with the fact that INTEM CT and
EXTEM CT were signiﬁcantly shorter over the 36 days in patients
who went on to develop VTE and suggests these may be more
clinically useful (Table 1). However, larger prospective studies
would be needed to clarify if ROTEM parameters are better at
predicting haemostatic balance and clinical outcome.
Importantly, this is also the ﬁrst study to demonstrate that for
any Clauss ﬁbrinogen, ALL patients had signiﬁcantly higher
FIBTEM MCF compared to normal controls and cardiac surgery
patients. Consistent with this at d29, 85% of Clauss ﬁbrinogen
results were below the reference range, whereas only 27% of
FIBTEM MCF result were below the reference range. It has long
been known that although Clauss ﬁbrinogen levels fall following
Asparaginase administration, VTE occurs more frequently than
bleeding including some thrombotic events when ﬁbrinogen
levels o1 g/l. Therefore, many clinical trials recommend avoid-
ance of monitoring in the absence of bleeding. The results of this
study provide some reassurance that the ﬁbrinogen component of
clot strength may in fact be underestimated by using the Clauss
assay. It is possible that FIBTEM results may be more physiologi-
cally reﬂective, perhaps because the FIBTEM MCF measures a
broader or different aspect of ﬁbrinogen function or because a
plasma component interferes with the Clauss assay.
This study also provides preliminary evidence that it may be
possible to deﬁne a group of ALL patients at high risk for
thrombosis before they commence treatment with ongoing
prothrombotic changes during treatment. It is possible that basic
laboratory markers (PLT, VWF:Ag, Clauss ﬁbrinogen) could be
combined with known clinical risk factors (such as age) to enable
prevention strategies to be targeted to patients at the highest VTE
risk. Reassuringly, the same laboratory parameters would be
associated with a low bleeding risk for thromboprophylaxis
administration with all VTE events occurring when platelets were
450 × 109/l.
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Figure 1. Correlation of FIBTEM MCF and Clauss ﬁbrinogen results in
ALL patients on GlobALL study (221 samples from 35 patients) and
normal controls (n= 20). Solid line demonstrates line of best ﬁt with
95% conﬁdence intervals (CIs) in dotted lines. Line is also drawn for
data from patients undergoing cardiac surgery immediately before
chest closure (n= 2146): Fibtem MCF= 1.55+5.67 ×Clauss ﬁbrinogen
(95% CI on the slope is 5.49–5.84 and y intercept is 1.138–1.95).
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